Punjab Bans 112 Substandard Drugs After CDSCO Warning
Punjab: In a decisive move to safeguard public health, the Punjab Government has banned the sale of 112 medicines declared "substandard" by the Central Drugs Standard Control Organisation (CDSCO). The action follows several recent incidents in which the consumption of certain drugs reportedly led to fatalities.
Earlier, the Medical Dialogues Team reported that the Central Drugs Standard Control Organization (CDSCO) identified 112 batches of medicines and medical products as "Not of Standard Quality" (NSQ) after samples tested in September 2025 by its central and state laboratories failed to meet required pharmacopeial and safety standards.
The list further includes Diclofenac Sodium and Paracetamol Tablets IP manufactured by Zydus Healthcare, Clobetasol Propionate Neomycin Sulfate and Miconazole Nitrate Cream manufactured by Macleods Pharmaceuticals, Ivabradine Tablets 5 mg manufactured by Hetero Labs.
Following this, the Punjab Government has imposed a strict ban on the sale of substandard medicines.
Balbir Singh, the state’s Health Minister, revealed the move in a social media message posted on Sunday, saying;
"Following a report from the CDSCO declaring these drugs to be of poor quality, the Health Department has ordered their immediate removal from the market. Citizens are advised to avoid using any of the listed medicines. Ensuring the health and safety of every resident remains the top priority of the Mann Government."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.